For the quarter ending 2025-09-30, AARD made $19,090K in revenue. -$16,316K in net income. Net profit margin of -85.47%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 13,737 | 13,145 | ||
| General and administrative expense | 3,966 | 2,703 | ||
| Credit loss - related party accounts receivable | 0 | 0 | ||
| Total operating expenses | 17,703 | 15,848 | ||
| Loss from operations | -17,703 | -15,848 | ||
| Unrealized gain (loss) on short-term investments | 36 | -7 | ||
| Interest and dividend income | 1,351 | 1,488 | ||
| Total other income, net | 1,387 | 1,481 | ||
| Net loss | -16,316 | -14,367 | ||
| Earnings per share, diluted | -0.75 | -0.66 | ||
| Net loss per share of common stock, basic | -0.75 | -0.66 | ||
| Weighted average number of shares outstanding, basic | 21,713,858 | 21,690,275 | ||
| Weighted-average shares used in net loss per share calculation, diluted | 21,713,858 | 21,690,275 | ||
Aardvark Therapeutics, Inc. (AARD)
Aardvark Therapeutics, Inc. (AARD)